Home LiteratureArticle Details
PMID: 14511336 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Inhibition of neurokinin-1-substance P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and the morphine-induced increase in CGRP expression in cultured dorsal root ganglion neurons.

The European journal of neuroscience ·Vol. 18 ·No. 6 ·2003-09-00 ·Pages 1572-83

Powell KJ, Quirion R, Jhamandas K

Abstract

Chronic treatment with opioid drugs such as morphine leads to the development of tolerance, which manifests as a loss of drug potency. The mechanisms underlying this phenomenon are poorly understood, but recent evidence suggests that increased activity of nociceptive sensory transmitters [calcitonin gene-related peptide (CGRP) and substance P] and other signalling messengers (prostaglandins) contribute to its development. Chronic intrathecal morphine administration to rats for 7 days produced analgesic tolerance. Co-administration of SR140333, a selective substance P receptor (neurokinin-1) antagonist, or nimesulide, a cyclooxygenase-2-selective inhibitor, augmented the acute effects of morphine, prevented morphine tolerance and reversed established tolerance. In cultured adult dorsal root ganglion neurons, exposure to morphine for 5 days increased the number of neurons expressing CGRP immunoreactivity. Co-exposure with the peptide CGRP receptor antagonist CGRP8-37, SR140333 or nimesulide prevented the morphine-induced increase in the expression of CGRP immunoreactivity. Additionally, BIBN4096BS, a nonpeptide CGRP receptor antagonist, stereoselectively produced similar effects. In summary, this investigation demonstrates that activity of CGRP and substance P contributes to both the induction and expression of opioid analgesic tolerance. Additionally, it highlights the involvement of prostaglandins generated by spinal cyclooxygenase-2 activity in the genesis of opioid tolerance. The neuropeptide and prostanoid activity contributing to tolerance is expressed at the level of the primary afferents terminating in the spinal cord. The combination of opioids with agents that block this activity may represent a useful strategy for the prevention as well as the reversal of clinical opioid tolerance.

MeSH Terms
Animals Behavior, Animal Calcitonin Gene-Related Peptide/metabolism Calcitonin Gene-Related Peptide Receptor Antagonists Cell Count Cells, Cultured Cyclooxygenase Inhibitors/pharmacology Dose-Response Relationship, Drug Drug Administration Schedule Drug Interactions Drug Tolerance/physiology Ganglia, Spinal/cytology Immunohistochemistry Male Morphine/adverse effects,pharmacology Morphine Dependence Neurokinin-1 Receptor Antagonists Neurons/drug effects,metabolism Pain Measurement/drug effects Piperidines/pharmacology Prostaglandins/metabolism Quinuclidines/pharmacology Rats Rats, Sprague-Dawley Receptors, Calcitonin Gene-Related Peptide/agonists Receptors, Neurokinin-1/metabolism Spinal Cord/drug effects Sulfonamides/pharmacology Time Factors
Chemicals
Calcitonin Gene-Related Peptide Receptor Antagonists Cyclooxygenase Inhibitors Neurokinin-1 Receptor Antagonists Piperidines Prostaglandins Quinuclidines Receptors, Calcitonin Gene-Related Peptide Receptors, Neurokinin-1 Sulfonamides SR 140333 Morphine Calcitonin Gene-Related Peptide nimesulide
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Powell Kelly J
Department Pharmacology & Toxicology, Queen's University, Kingston, ON, Canada K7L 3N6.
Quirion Remi
Jhamandas Khem
Article Info
Journal
The European journal of neuroscience
Abbr.
Eur J Neurosci
ISSN
0953-816X
Published
2003-09-00
Pages
1572-83
Language
English
Region
France
NLM ID
8918110
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com